BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is very pleased to announce positive results from a phase 1 clinical study of maveropepimut-S ("MVP-S"
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-17 8:00 AM EST | BioVaxys Technology Corp.
Envoy Medical Secures New Australian Patent for Cochlear Implant Innovation Aimed at Enhancing Input Signal-to-Noise Ratio
White Bear Lake, Minnesota--(Newsfile Corp. - December 16, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of Australian Patent No. 2022229818, granted by the Australian Patent Office on October 16, 2025. The newly issued patent strengthens the Company's global IP portfolio in an important international market that is also the home country of its larges
Biotechnology, Healthcare and Hospitals
2025-12-16 8:00 AM EST | Envoy Medical, Inc.
Mayo Clinic Jacksonville Comes Online as Third Site in Breathe BioMedical's Ongoing Multi-Center Clinical Study to Develop a Breath Test for Early Detection of Breast Cancer in Females with Dense Breasts
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - December 16, 2025) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced the launch of the third site in its large multi-center observational collection protocol study to advance the development of its breath test for the early detection
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-12-16 8:00 AM EST | Breathe BioMedical Inc.
HealthPlus Staffing Signs First Franchisee as It Launches a Revolutionary Healthcare Recruitment Franchise System
Wellington, Florida--(Newsfile Corp. - December 15, 2025) - HealthPlus Staffing, one of the nation's fastest-growing healthcare recruitment firms and a 2025 Inc. Regionals honoree, today announced the official launch of its healthcare recruitment franchise system alongside the signing of its first franchisee, awarding the exclusive South Florida Primary Care territory to respected business leader Ryan Kuhlman. This milestone marks the beginning of a new era in healthcare staffin
2025-12-15 6:15 PM EST | HealthPlus Staffing
James Anderson Provides Update on Holdings of MyndTec Inc.
Detroit, Michigan--(Newsfile Corp. - December 15, 2025) - James Anderson (the "Investor") announces update to his ownership of common shares in the capital of MyndTec Inc. (the "Issuer") (the "Common Shares") and common share purchase warrants of the Issuer (the "Warrants"). On December 12, 2025, the Issuer completed the ninth tranche (the "Ninth Tranche") of a private placement of units ("Units") announced on January 30, 2025. 553,926 Units we
Technology, Healthcare and Hospitals, Health
2025-12-15 5:25 PM EST | James Anderson
Adia Nutrition Inc. Announces IRB Approval from BeyondBound for Adia Med's Autism Clinical Study
Winter Park, Florida--(Newsfile Corp. - December 15, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its Adia Med subsidiary, today announced that the independent Institutional Review Board (IRB) BeyondBound has approved the company's patent-pending clinical study protocol focused on Autism Spectrum Disorder (ASD).
Healthcare and Hospitals, Health
2025-12-15 10:30 AM EST | Adia Nutrition Inc.
Apyron Pioneering Next Generation Pain Management Solutions
Atlanta, Georgia--(Newsfile Corp. - December 15, 2025) - Apyron, Inc. is a medical technology company with a product portfolio designed to address chronic pain and joint-related disorders, with a core value to restore mobility in patients and provide them agency over their therapy. Apyron's product portfolio is being developed to address two major contributors to disability — chronic lower back pain and joint disease. Chronic pain markets account for over $384 million of healthcare spe
Biotechnology, Healthcare and Hospitals, Health
2025-12-15 9:00 AM EST | Apyron, Inc.
CareRx Announces Q4 2025 Dividend
Toronto, Ontario--(Newsfile Corp. - December 15, 2025) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today announced that the Company's Board of Directors has declared a dividend of CAD$0.02 per outstanding common share of the Company ("Common Shares"), payable on January 21, 2026, to holders of record of Common Shares as of the close of business on
2025-12-15 7:30 AM EST | CareRx Corporation
NervGen Pharma Announces Proposed Amendment to Warrants
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Company intends to amend 5,075,000 common share purchase warrants (the "2022 Warrants") that were issued pursuant to a private placement of units that c
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-12 7:51 PM EST | NervGen Pharma Corp.
MyndTec Inc. Completes Ninth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 12, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the ninth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The ninth tranche of the private placement consists of 553,926 Units of the Company (the "Units") at a price of $0.20 p
Technology, Healthcare and Hospitals, Health
2025-12-12 5:39 PM EST | MyndTec Inc.
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commenced a non-brokered private placement of units of the Company ("Units") to raise up to $CAN 2,000,000 (&#
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-12-12 5:00 PM EST | Theralase Technologies Inc.
Healthcare Special Opportunities Fund Announces December 2025 Quarterly Distribution
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - LDIC Inc. (the "Manager"), the manager of Healthcare Special Opportunities Fund (TSX: MDS.UN) (the "Fund"), a closed-end investment fund, today announces the quarterly distribution of CDN$0.06136 per Class A unit and US$0.05468 per Class U unit. The distribution will be paid on or before December 30, 2025, to unitholders of record on December 15, 2025. For further information please co
Banking / Financial Services, Healthcare and Hospitals
2025-12-12 9:55 AM EST | Healthcare Special Opportunities Fund
Envoy Medical Completes First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - December 10, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the completion of the first set of activations in the final stage of the pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant. These activations were performed at Shohet Ear Associates in Seal Beach, California and the C
Biotechnology, Healthcare and Hospitals
2025-12-10 8:00 AM EST | Envoy Medical, Inc.
Relief AI Inc. Announces Significant Milestones as Its Platform Adoption Accelerates
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Relief AI Inc. (the "Company "or "Relief AI) is pleased to provide an update on the significant progress made over the past year as the company continues its mission to deliver the most advanced, holistic, and effective workplace wellness and well-being platform available today. Relief AI is a leading-edge workplace well-being platform designed specifically to identify and help employees address early signs of workplace bur
Technology, Healthcare and Hospitals, Health
2025-12-10 7:00 AM EST | Relief AI Inc.
HEALWELL AI Appoints Ian Kidson to Board of Directors
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "
Technology, Healthcare and Hospitals
2025-12-10 3:15 AM EST | HEALWELL AI
Adia Nutrition Inc. Files SEC Form 10 as Strategic Step Toward Full Reporting Status
Winter Park, Florida--(Newsfile Corp. - December 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), announced today that, with the assistance of Adia's Chief Financial Officer, and following review by the Company's auditing accountant, its Form 10 registration statement was prepared and submitted by Adia's corporate accountant and legal counsel to the U.S. Securities and Exchange Commission (SEC).
Healthcare and Hospitals, Health
2025-12-08 9:00 AM EST | Adia Nutrition Inc.
Correction to MyndTec Inc. Press Release Issued December 3, 2025 Regarding Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 5, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), announced today a correction to its press release titled "MyndTec Inc. Completes Eighth Tranche of Non-Brokered Private Placement" issued on December 3, 2025 (the "Initial Press Release"). The Initial Press Release incorrectly stated the number of units issued under the eighth tranche of the private placement Offering as 351,475 Units, the aggregate
Technology, Healthcare and Hospitals, Health
2025-12-05 4:30 PM EST | MyndTec Inc.
Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient
White Bear Lake, Minnesota--(Newsfile Corp. - December 4, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it will host a fireside chat on Thursday, December 11, 2025, at 4:30 P.M. ET featuring a conversation between CEO Brent Lucas and Craig Eggert, the first patient to receive the Acclaim™ cochlear implant. Event: Envoy Medical Fireside Chat
Biotechnology, Healthcare and Hospitals
2025-12-04 8:00 AM EST | Envoy Medical, Inc.
MyndTec Inc. Completes Eighth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 3, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the eighth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The eighth tranche of the private placement consists of 351,475 Units of the Company (the "Units") at a price of $0.20
Technology, Healthcare and Hospitals, Health
2025-12-03 5:00 PM EST | MyndTec Inc.
Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions are Underway
Ad hoc announcement pursuant to Art. 53 LR 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) Both studies reached statistically significant endpoints in TAHC (Target-Area Hair Count), with one reaching 539% relative improvement to placebo and the second study reaching 168% relative improvement to placebo Positive safety profile demonstrated
Healthcare and Hospitals, Health
2025-12-03 1:12 AM EST | Cosmo Pharmaceuticals N.V.